Clinical factors predicting disease course in Crohn's disease

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 41-45

  Eglinton, Tim W ^a,b   Gearry, Richard B ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Azathioprine; Crohn's disease; Monoclonal antibodies; Perianal disease; Smoking; Surgery

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; INFLIXIMAB; STEROID;

ANUS DISEASE; BIOLOGICAL THERAPY; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG USE; GENETIC MARKER; HUMAN; ILEUM DISEASE; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PHENOTYPE; PREDICTION; PROGNOSIS; RISK FACTOR; SMOKING;

EID: 77649119123     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.76     Document Type: Note

References (35)

1. Lakatos PL, Czegledi Z, Szamosi T et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J. Gastroenterology 15(28), 3504-3510 (2009).
2. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. 92(12 Suppl.), S5-S11 (1997).
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6), 1504-1517 (2004).
4. Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand. J. Gastroenterol. 36(1), 2-15 (2001).
5. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8(4), 244-250 (2002).
6. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification, changing pattern over the course of the disease. Gut 49(6), 777-782 (2001).
7. Romberg-Camps MJ, Dagnelie PC, Kester AD et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am. J. Gastroenterol. 104(2), 371-383 (2009).
8. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 130(3), 650-656 (2006).
9. Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 55(8), 1124-1130 (2006).
10. Tarrant KM, Barclay ML, Frampton CMA, Gearry RB. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am. J. Gastroenterol. 103(12), 3082-3093 (2008).
11. Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn's disease, analysis according to the Vienna classification and clinical activity. Inflamm. Bowel Dis. 7(4), 306-313 (2001).
12. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol. 43(8), 948-954 (2008).
13. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease, effect on localisation and clinical course. Gut 33(6), 779-782 (1992).
14. Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. Am. J. Gastroenterol. 98(2), 363-368 (2003).
15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. 170(Suppl.), 2-6; discussion 16-19 (1989).
16. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19(Suppl. A), 5-36 (2005).
17. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 6(1), 8-15 (2000).
18. Chow DK, Leong RW, Lai LH et al. Changes in Crohn's disease phenotype over time in the Chinese population, validation of the Montreal classification system. Inflamm. Bowel. Dis. 14(4), 536-541 (2008).
19. Somerville KW, Logan RF, Edmond M, Langman MJ. Smoking and Crohn's disease. Br. Med. J. (Clin. Res. Ed.) 289(6450), 954-956 (1984).
20. Tobin MV, Logan RF, Langman MJ, McConnell RB, Gilmore IT. Cigarette smoking and inflammatory bowel disease. Gastroenterology 93(2), 316-321 (1987).
21. Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB. Cigarette smoking in Crohn's disease. Am. J. Gastroenterol. 84(1), 31-33 (1989).
22. Louis E, Michel V, Hugot JP et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 52(4), 552-557 (2003).
23. Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease, top-down or step-up? Dig. Dis. 25(3), 260-266 (2007).
24. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. J. Gastroenterol. 95(11), 3189-3194 (2000).
25. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119(4), 895-902 (2000).
26. Hommes D, Baert F, Van Assche G. A randomized controlled trial evaluating the ideal management for Crohn's disease, top-down versus tep-up strategies. Gastroenterology 128(Suppl. 2), A577 (2005).
27. Reese GE, Constantinides VA, Simillis C et al. Diagnostic precision of anti- Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am. J. Gastroenterol. 101(10), 2410-2422 (2006).
28. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels, facts and perspectives. Inflamm. Bowel. Dis. 13(12), 1561-1566 (2007).
29. Ferrante M, Henckaerts L, Joossens M et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56(10), 1394-1403 (2007).
30. Gearry RB, Roberts RL, Burt MJ et al. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm. Bowel Dis. 13(10), 1220-1227 (2007).
31. Armuzzi A, Ahmad T, Ling KL et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52(8), 1133-1139 (2003).
32. Vermeire S. Review article, genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 24(Suppl. 3), 2-10 (2006).
33. Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article, appropriate use of corticosteroids in Crohn's disease. Aliment. Pharmacol. Ther. 26(3), 313-329 (2007).
34. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease, TREAT registry. Clin. Gastroenterol. Hepatol. 4(5), 621-630 (2006).
35. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies, systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275-2285 (2006).